Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06283745 · ClinicalTrials.gov registry record · NA

Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia

A NA study of Paraosmia, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06283745 is a NA study of Paraosmia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06283745, a NA study of Paraosmia, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia.

Conditions Studied

Interventions

  • OTHER Saline
  • OTHER Platelet-rich Plasma (PRP)

Study Locations (1)

California

  • Stanford Sinus Center / Stanford University School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-11-23
Est. Completion 2027-03-22
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT06283745

The ClinicalTrials.gov registry entry for NCT06283745 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Paraosmia appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT06283745 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06283745 about?

NCT06283745 is a clinical study titled "Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia". This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It...

What is the current status of trial NCT06283745?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-11-23. Estimated completion is 2027-03-22.

What conditions does trial NCT06283745 study?

This clinical trial studies the following conditions: Paraosmia.

What interventions are being tested in trial NCT06283745?

The interventions under investigation include: Saline (OTHER), Platelet-rich Plasma (PRP) (OTHER).

Who is sponsoring clinical trial NCT06283745?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06283745 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.